These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 17521214)

  • 1. Hormone-refractory prostate cancer: where are we going?
    Di Lorenzo G; Autorino R; Figg WD; De Placido S
    Drugs; 2007; 67(8):1109-24. PubMed ID: 17521214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent progress in management of advanced prostate cancer.
    Kantoff P
    Oncology (Williston Park); 2005 Apr; 19(5):631-6. PubMed ID: 15945343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic options for hormone-refractory prostate cancer in 2007.
    Hadaschik BA; Gleave ME
    Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
    Berry W; Eisenberger M
    Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Taxanes in the chemotherapy of hormone-refractory prostate carcinoma].
    Johannsen M; Wilke K; Schnorr D; Loening SA
    Urologe A; 2004 Feb; 43(2):160-7. PubMed ID: 14991117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future directions in the treatment of androgen-independent prostate cancer.
    Petrylak DP
    Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments.
    Mancuso A; Oudard S; Sternberg CN
    Crit Rev Oncol Hematol; 2007 Feb; 61(2):176-85. PubMed ID: 17074501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New perspectives in the therapy of castration resistant prostate cancer.
    Rescigno P; Buonerba C; Bellmunt J; Sonpavde G; De Placido S; Di Lorenzo G
    Curr Drug Targets; 2012 Dec; 13(13):1676-86. PubMed ID: 23043326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hormone-refractory prostate cancer].
    Alexandre I; Rixe O
    Ann Urol (Paris); 2007 Apr; 41(2):47-55. PubMed ID: 17486912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promising novel cytotoxic agents and combinations in metastatic prostate cancer.
    Bradley DA; Hussain M
    Cancer J; 2008; 14(1):15-9. PubMed ID: 18303478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolving role of immunotherapy in prostate cancer.
    Gerritsen WR
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Promising new treatment options for metastatic androgen-independent prostate cancer].
    Tan W
    Actas Urol Esp; 2007 Jun; 31(6):680-5. PubMed ID: 17896565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
    Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
    Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Docetaxel for metastatic prostate cancer: early is better].
    Gietema JA; Oosting SF
    Ned Tijdschr Geneeskd; 2016; 160():D215. PubMed ID: 27405569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Castration-refractory prostate cancer: New drugs in the pipeline.
    Schrijvers D; Van Erps P; Cortvriend J
    Adv Ther; 2010 May; 27(5):285-96. PubMed ID: 20532721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel agents and targets in managing patients with metastatic prostate cancer.
    Tan WW
    Cancer Control; 2006 Jul; 13(3):194-8. PubMed ID: 16885915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
    Di Lorenzo G; De Placido S
    Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer.
    Salzberg M; Rochlitz C; Morant R; Thalmann G; Pedrazzini A; Roggero E; Schönenberger A; Knuth A; Borner M
    Onkologie; 2007 Jul; 30(7):355-60. PubMed ID: 17596743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials.
    van Soest RJ; de Wit R
    BMC Med; 2015 Dec; 13():304. PubMed ID: 26695172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.